HK Stock Market Move | SMOORE INTL (06969) rose another 4% in early trading, with the stock incentive plan targeting market value directly anchored. HNB products are expected to increase volume.
Simone International (06969) surged another 4% in early trading, as of the time of publication, it had risen by 2.83% to HK$14.52, with a turnover of HK$4.92 billion.
SMOORE INTL (06969) rose another 4% in early trading, rising 2.83% to 14.52 Hong Kong dollars as of the time of writing, with a turnover of 4.92 billion Hong Kong dollars.
On the news front, on December 27th, SMOORE INTL announced plans to conditionally grant 61 million share options to Mr. Chen Ziping, the chairman of the board, executive director, and major shareholder of the company. Shenwan Hongyuan Group pointed out that the performance target is directly anchored to the market value, with an ambitious target market value of 500 billion Hong Kong dollars for all shares. As of December 27, 2024, SMOORE INTL's closing market value was 69.6 billion Hong Kong dollars.
Zheshang released a report stating that SMOORE INTL's core customer British American Tobacco (BAT) has launched a new type of non-burning tobacco product (HNB). The bank believes that the new generation of Glo Hilo products, whether compared horizontally to leading products on the market like IQOS iluma i, or vertically to the preceding generation, have significantly improved performance and user experience. They are optimistic about its gradual expansion into more markets from 2025 to 2026 and increasing demand.
Related Articles

FLAT GLASS (06865) plans to distribute a final dividend of 0.15 yuan per share.

Cathay Pacific Airways (00293) passenger load factor increased by 24% year-on-year in March.

GlaxoSmithKline plc Sponsored ADR (GSK.US) Belantamab mafodotin has been approved for sale in China.
FLAT GLASS (06865) plans to distribute a final dividend of 0.15 yuan per share.

Cathay Pacific Airways (00293) passenger load factor increased by 24% year-on-year in March.

GlaxoSmithKline plc Sponsored ADR (GSK.US) Belantamab mafodotin has been approved for sale in China.

RECOMMEND

Hong Kong Hard‑Tech Companies Enhance Canton Fair Presence As Veterans And Newcomers Expand International Networks
17/04/2026

Thousand‑Fold Oversubscription In Hong Kong IPOs Signals Multiple Market Shifts
17/04/2026

Rising Compute Costs Drive Industry Price Increases As Institutions Expect Internet Firms To Outperform In Q1
17/04/2026


